Cannabis Schedule III Rescheduling Impact on Medical Research and Patients
The potential rescheduling of cannabis from Schedule I to Schedule III represents a significant regulatory shift that could reduce research barriers and accelerate clinical investigation. Cannabis schedule III rescheduling would lower DEA registration…
Patient First Coalition Supports DEA’s Medical Cannabis Review Process Providing Experts …
✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyResearchMedical CannabisPharmaceuticalDEASchedule IIIPatient Advocacy Why This Matters Clinicians need to…
Federal Schedule III shift triggers D.C., Maryland cannabis uncertainty – Outlaw Report
Federal rescheduling of cannabis to Schedule III would fundamentally change how physicians approach cannabis medicine, moving from state recommendations to federal prescriptions. This regulatory shift creates both opportunities for standardized cannabis…
What the 2026 DOJ Rescheduling Order Means in Practice
On April 23, 2026, the U.S. DOJ moved state-licensed medical cannabis to Schedule III, the first federal acknowledgment of accepted medical value in 55 years. Dr. Caplan breaks down what actually changed for patients, physicians, and the research…
Trump administration moves medical marijuana to Schedule III – WLOX
✦ New CED Clinical Relevance #76Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic PolicyResearchFederal RegulationMedical…
Terrapin calls for state action following DOJ’s medical marijuana rescheduling | News
✦ New CED Clinical Relevance #76Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Federal PolicyMedical…
New Mexico cannabis businesses see tax break potential after federal rescheduling – KOB 4
✦ New CED Clinical Relevance #82High Clinical Relevance Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News | CED Clinic PolicyAccessEconomicsRegulationSchedule…
Medical marijuana moves to Schedule III, boosting research and tax relief, but no change to …
✦ New CED Clinical Relevance #76Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic PolicyResearchSchedule IiiAccessRegulation…
UNLV scientists say the federal move reclassifying cannabis to Schedule III won’t legalize it …
✦ New CED Clinical Relevance #82High Clinical Relevance Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News | CED Clinic PolicyRegulationSchedule IiiMedical…
What the DOJ Cannabis Order Means for Patients and Clinicians
The medical cannabis Schedule III order is a major federal policy change, but it is not the same as new clinical proof. This Evidence Watch explains what the DOJ action may mean for research access, patient care, and regulated medical cannabis programs.…